Experimental cancer drug BBI-825 tested in early trial

NCT ID NCT06299761

Terminated Disease control Sponsor: Boundless Bio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an oral drug called BBI-825 in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BBI-825 (an oral ribonucleotide reductase inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1/2) trial that was terminated early with only 19 participants, so results are limited and may not apply to larger populations. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology

Irving, Texas, 75039, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
Sarcoma Oncology Research Center

Santa Monica, California, 90403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.